Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

NCT05151471 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

202

Enrollment

INDUSTRY

Sponsor class

Stopped Futility Analysis of parent study MT-1186-A02 was met.

Conditions

ALS

Interventions

DRUG: MT-1186
DRUG: Placebo

Sponsor

Tanabe Pharma America, Inc.